Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.
Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).
Recent advancements suggest that a significant competitor to Keytruda, the world’s top-selling cancer therapy, might be emerging.,Keytruda, manufactured b... "Lorem ipsum dolor sit amet, consectetur ...